Literature DB >> 23983982

A successful treatment strategy for clozapine-induced parotid swelling: a clinical case and systematic review.

Vyasa Immadisetty1, Pradeep Agrawal.   

Abstract

Parotid gland swelling is a less frequently reported side effect of clozapine and has no licensed treatment. A 58-year-old man treated with clozapine for treatment-resistant schizophrenia developed bilateral painful parotid swellings and hypersalivation. Initial trials of dose alteration and antihypersalivatory medication had limited success. A combination of benzatropine and terazosin was successful in treating the parotid hyperplasia. Clozapine was the probable cause of parotid swelling in our case, as established using the Naranjo adverse drug reaction probability scale and World Health Organization causality categories. Literature for treatments of clozapine-induced parotid gland swellings was reviewed. None of the published articles suggested a treatment regimen for clozapine-induced parotid hyperplasia. Most reports only highlighted the occurrence of salivary gland swelling with clozapine. Others mentioned management strategies, which included spontaneous resolution, or resolution on discontinuing clozapine. One report, a trial with benzatropine and ipratropium, had variable success. In this case the re-emergence of parotid swelling when terazosin and benzatropine doses were missed followed by a quick resolution upon recompliance, goes some way in proving that this combination is indeed effective. The combination of terazosin and benzatropine appears to have a role in treating parotid gland swellings induced by clozapine.

Entities:  

Keywords:  Benzatropine; clozapine; parotid; swelling; terazosin

Year:  2012        PMID: 23983982      PMCID: PMC3736957          DOI: 10.1177/2045125312455187

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  15 in total

Review 1.  Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.

Authors:  Maria Augusta Raggi; Roberto Mandrioli; Cesare Sabbioni; Vincenzo Pucci
Journal:  Curr Med Chem       Date:  2004-02       Impact factor: 4.530

2.  Tolerability of long term clozapine treatment.

Authors:  M Schmauss; R Wolff; A Erfurth; E Rüther
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data.

Authors:  H Ben-Aryeh; T Jungerman; R Szargel; E Klein; D Laufer
Journal:  Biol Psychiatry       Date:  1996-06-01       Impact factor: 13.382

4.  Possible association of parotitis with clozapine.

Authors:  D Robinson; H Fenn; J Yesavage
Journal:  Am J Psychiatry       Date:  1995-02       Impact factor: 18.112

Review 5.  Clozapine versus typical neuroleptic medication for schizophrenia.

Authors:  K Wahlbeck; M Cheine; M A Essali
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 6.  Clozapine-induced hypersalivation.

Authors:  L Davydov; S R Botts
Journal:  Ann Pharmacother       Date:  2000-05       Impact factor: 3.154

Review 7.  Management of the adverse effects of clozapine.

Authors:  C R Young; M B Bowers; C M Mazure
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

Review 8.  Pharmacologic therapy for prostatism.

Authors:  M M Lieber
Journal:  Mayo Clin Proc       Date:  1998-06       Impact factor: 7.616

Review 9.  Update on the clinical efficacy and side effects of clozapine.

Authors:  A Safferman; J A Lieberman; J M Kane; S Szymanski; B Kinon
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

10.  Duration of psychosis and outcome in first-episode schizophrenia.

Authors:  A D Loebel; J A Lieberman; J M Alvir; D I Mayerhoff; S H Geisler; S R Szymanski
Journal:  Am J Psychiatry       Date:  1992-09       Impact factor: 18.112

View more
  2 in total

Review 1.  Rare and very rare adverse effects of clozapine.

Authors:  Pasquale De Fazio; Raffaele Gaetano; Mariarita Caroleo; Gregorio Cerminara; Francesca Maida; Antonio Bruno; Maria Rosaria Muscatello; Maria Jose Jaén Moreno; Emilio Russo; Cristina Segura-García
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-06       Impact factor: 2.570

Review 2.  A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.

Authors:  Andy Wolff; Revan Kumar Joshi; Jörgen Ekström; Doron Aframian; Anne Marie Lynge Pedersen; Gordon Proctor; Nagamani Narayana; Alessandro Villa; Ying Wai Sia; Ardita Aliko; Richard McGowan; Alexander Ross Kerr; Siri Beier Jensen; Arjan Vissink; Colin Dawes
Journal:  Drugs R D       Date:  2017-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.